The role of TNFR2+ Tregs in COVID-19: An overview and a potential therapeutic strategy

Life Sci. 2021 Dec 1:286:120063. doi: 10.1016/j.lfs.2021.120063. Epub 2021 Oct 19.

Abstract

COVID-19 is a multi-faceted disease ranging from asymptomatic to severely ill condition that primarily affects the lungs and could advance to other organs as well. It's causing factor, SARS-CoV-2 is recognized to develop robust cell-mediated immunity that responsible to either control or exaggerate the infection. As an important cell subset that control immune responses and are significantly dysregulated in COVID-19, Tregs is proposed to be considered for COVID-19 management. Among its hallmark, TNFR2 is recently recognized to play important role in the function and survival of Tregs. This review gathers available TNFR2 agonists to directly target Tregs as a potential approach to overcome immune dysregulation that affect the severity in COVID-19. Furthermore, this review performs a rigid body docking of TNF-TNFR2 interaction and such interaction with TNFR2 agonist to predict the optimal targeting approach.

Keywords: Immune tolerance; Immunotherapy; SARS-CoV-2; TNF-TNFR2.

Publication types

  • Review

MeSH terms

  • COVID-19 / immunology*
  • COVID-19 / therapy*
  • COVID-19 / virology
  • Humans
  • Lymphocyte Activation
  • Receptors, Tumor Necrosis Factor, Type II / physiology*
  • SARS-CoV-2 / isolation & purification
  • T-Lymphocytes, Regulatory / immunology*

Substances

  • Receptors, Tumor Necrosis Factor, Type II